This review shows the brain tissue integrity data and safety profile of new oral agents for treatment of of RRMS such as: BG-12 , Teriflunomide, Fingolimod,Laquinimod Natalizumab
DEFINE and CONFIRM study shows BG-12 and Fingolimod more effective in reduction of progression and remession clinically and radiologically than placebo among RRMS patient
The patients must be screened with cardiological assesment if they have risk of cardiovascular diseases or on antiarrythmic medications before fingolimod therapy for safety.
Medscape Neurology news (www.Medscape.com)...
Disclaimer In his capacity as the website owner and because of the full permissions that he has, all of the contents of the faculty member’s website including texts, images, researches and any other media are his responsibility. Therefore, the university disclaim any responsibility on this regard.
Copyright © Deanship of IT & Distance Learning 2018, 1440 H